ESR1 and breast cancer: Administration of a PROTAC BET inhibitor, ARV-825, extended the growth arrest initiated by fulvestrant plus palbociclib in p53 wild-type MCF-7 cells, p53 mutant T47D cells and Rb-deleted ER+ breast cancer cell lines [8].